FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169335265> ?p ?o ?g. }

• W2169335265 endingPage "147" @default.
• W2169335265 startingPage "139" @default.
• W2169335265 abstract "The treatment of symptoms of seasonal allergic rhinitis often requires the use of a decongestant to improve nasal congestion, along with an antihistamine to adequately control other nasal, as well as nonnasal symptoms.In this double-blind, placebo-controlled, multicenter study, 874 patients with moderate to severe symptoms of seasonal allergic rhinitis were treated with one of the following: SCH 434 QD (a combination of 10 mg of loratadine in the coating and 240 mg of pseudoephedrine sulfate in an extended-release core) once daily, 10 mg of loratadine once daily, 120 mg of pseudoephedrine sulfate every 12 hours, or placebo for 2 weeks.SCH 434 QD was consistently superior to placebo in controlling the symptoms of seasonal allergic rhinitis. Composite symptom scores (total, total nasal, and total nonnasal) were reduced significantly in patients treated with SCH 434 QD as compared with placebo (p < 0.01). When compared with its individual components, reductions in mean symptom scores were consistently greater, numerically, in patients treated with SCH 434 QD than in patients who were treated with either loratadine or pseudoephedrine alone. SCH 434 QD was superior to pseudoephedrine in reducing nonnasal symptoms at all time points (p < 0.01), and superior to loratadine in relieving nasal stuffiness at end point (p < 0.01). In the physicians' evaluation of therapeutic response, the SCH 434 QD group had the greatest number of patients with a good or excellent response at end point (58%). All treatments were generally well tolerated with no serious or unusual adverse events. Insomnia and nervousness, adverse events commonly associated with pseudoephedrine, were noted in a significantly greater number of patients treated with SCH 434 QD or pseudoephedrine (p < or = 0.04) as compared with those treated with loratadine or placebo.The results of the study demonstrate that SCH 434 QD is more effective than placebo or either of its components alone in the treatment of seasonal allergic rhinitis." @default.
• W2169335265 created "2016-06-24" @default.
• W2169335265 creator A5019346006 @default.
• W2169335265 creator A5021219324 @default.
• W2169335265 creator A5030622767 @default.
• W2169335265 creator A5058570293 @default.
• W2169335265 creator A5059416402 @default.
• W2169335265 creator A5070339060 @default.
• W2169335265 creator A5078984977 @default.
• W2169335265 creator A5083496019 @default.
• W2169335265 creator A5083626960 @default.
• W2169335265 creator A5088842944 @default.
• W2169335265 date "1995-08-01" @default.
• W2169335265 modified "2023-09-30" @default.
• W2169335265 title "Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis" @default.
• W2169335265 cites W188068504 @default.
• W2169335265 cites W2013629548 @default.
• W2169335265 cites W2015008357 @default.
• W2169335265 cites W2015245464 @default.
• W2169335265 cites W2021522284 @default.
• W2169335265 cites W2022870596 @default.
• W2169335265 cites W2034220779 @default.
• W2169335265 cites W2042740947 @default.
• W2169335265 cites W2061025681 @default.
• W2169335265 cites W2066964307 @default.
• W2169335265 cites W2121979920 @default.
• W2169335265 cites W2135694726 @default.
• W2169335265 cites W2142516619 @default.
• W2169335265 cites W2147578928 @default.
• W2169335265 cites W2242813565 @default.
• W2169335265 cites W2407538661 @default.
• W2169335265 cites W2413474188 @default.
• W2169335265 cites W2430545434 @default.
• W2169335265 doi "https://doi.org/10.1016/s0091-6749(95)70001-3" @default.
• W2169335265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7636050" @default.
• W2169335265 hasPublicationYear "1995" @default.
• W2169335265 type Work @default.
• W2169335265 sameAs 2169335265 @default.
• W2169335265 citedByCount "63" @default.
• W2169335265 countsByYear W21693352652012 @default.
• W2169335265 countsByYear W21693352652013 @default.
• W2169335265 countsByYear W21693352652015 @default.
• W2169335265 countsByYear W21693352652018 @default.
• W2169335265 countsByYear W21693352652020 @default.
• W2169335265 countsByYear W21693352652022 @default.
• W2169335265 countsByYear W21693352652023 @default.
• W2169335265 crossrefType "journal-article" @default.
• W2169335265 hasAuthorship W2169335265A5019346006 @default.
• W2169335265 hasAuthorship W2169335265A5021219324 @default.
• W2169335265 hasAuthorship W2169335265A5030622767 @default.
• W2169335265 hasAuthorship W2169335265A5058570293 @default.
• W2169335265 hasAuthorship W2169335265A5059416402 @default.
• W2169335265 hasAuthorship W2169335265A5070339060 @default.
• W2169335265 hasAuthorship W2169335265A5078984977 @default.
• W2169335265 hasAuthorship W2169335265A5083496019 @default.
• W2169335265 hasAuthorship W2169335265A5083626960 @default.
• W2169335265 hasAuthorship W2169335265A5088842944 @default.
• W2169335265 hasConcept C126322002 @default.
• W2169335265 hasConcept C141071460 @default.
• W2169335265 hasConcept C142724271 @default.
• W2169335265 hasConcept C197934379 @default.
• W2169335265 hasConcept C204787440 @default.
• W2169335265 hasConcept C27081682 @default.
• W2169335265 hasConcept C2776880894 @default.
• W2169335265 hasConcept C2777844070 @default.
• W2169335265 hasConcept C2778311950 @default.
• W2169335265 hasConcept C2778385066 @default.
• W2169335265 hasConcept C2778984665 @default.
• W2169335265 hasConcept C2779777004 @default.
• W2169335265 hasConcept C2780734495 @default.
• W2169335265 hasConcept C2910477827 @default.
• W2169335265 hasConcept C42219234 @default.
• W2169335265 hasConcept C71924100 @default.
• W2169335265 hasConceptScore W2169335265C126322002 @default.
• W2169335265 hasConceptScore W2169335265C141071460 @default.
• W2169335265 hasConceptScore W2169335265C142724271 @default.
• W2169335265 hasConceptScore W2169335265C197934379 @default.
• W2169335265 hasConceptScore W2169335265C204787440 @default.
• W2169335265 hasConceptScore W2169335265C27081682 @default.
• W2169335265 hasConceptScore W2169335265C2776880894 @default.
• W2169335265 hasConceptScore W2169335265C2777844070 @default.
• W2169335265 hasConceptScore W2169335265C2778311950 @default.
• W2169335265 hasConceptScore W2169335265C2778385066 @default.
• W2169335265 hasConceptScore W2169335265C2778984665 @default.
• W2169335265 hasConceptScore W2169335265C2779777004 @default.
• W2169335265 hasConceptScore W2169335265C2780734495 @default.
• W2169335265 hasConceptScore W2169335265C2910477827 @default.
• W2169335265 hasConceptScore W2169335265C42219234 @default.
• W2169335265 hasConceptScore W2169335265C71924100 @default.
• W2169335265 hasIssue "2" @default.
• W2169335265 hasLocation W21693352651 @default.
• W2169335265 hasLocation W21693352652 @default.
• W2169335265 hasOpenAccess W2169335265 @default.
• W2169335265 hasPrimaryLocation W21693352651 @default.
• W2169335265 hasRelatedWork W172522551 @default.
• W2169335265 hasRelatedWork W1908067884 @default.
• W2169335265 hasRelatedWork W2026851304 @default.
• W2169335265 hasRelatedWork W2042740947 @default.

• next